Compare Danaher Corporation (DHR) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Oxford Lane Capital Corp — how do they compare? Danaher Corporation trades at $201.25 (market cap $140.88B), while Oxford Lane Capital Corp trades at $9.14 (market cap $891.54M). The key difference: Danaher Corporation is far larger — about 158× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.29%). Which is the better fit depends on your goals.
| DHR | OXLC | |
|---|---|---|
Market Cap | $140.88B | $891.54M |
Sector | Health | Financials |
52-Week High | $242.05 | $20.80 |
52-Week Low | $161.91 | $8.15 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
OXLC trades at $9.19, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. The company reported a net income margin of 100.85% for 2025, but earnings misses and a sharp revenue decline to -$580M in 2026 highlight volatility. Recent news includes dividend declarations and a net asset value update from Oxford Lane Capital on June 15, 2026.
Outlook is cautious due to inconsistent earnings and high yield sustainability concerns. Risks include NAV decay and competitive pressures, while opportunities lie in dividend income. Analyst consensus is split, with 50% buy ratings but significant sell coverage citing fund performance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
